產(chǎn)品編號 | BIO1018SM |
英文名稱(chēng) | Anti-PD-1 & PD-L1 Reference Antibody (Reozalimab Biosimilar) |
別 名 | Angiopoietin 2 & VEGF; Reozalimab |
抗體來(lái)源 | |
克隆類(lèi)型 | Monoclonal |
交叉反應 | Human |
產(chǎn)品應用 |
not yet tested in other applications. optimal dilutions/concentrations should be determined by the end user. |
理論分子量 | 143.84kDa |
性 狀 | Lyophilized |
亞 型 | IgG-like |
純化方法 | Protein A |
緩 沖 液 | 100 mM Pro-Ac 20mM Arg pH 5.0 |
保存條件 | -80°C for 2 years under sterile conditions; -20°C for 1 year under sterile conditions;Avoid repeated freeze-thaw cycles. |
注意事項 | This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications. |
PubMed | PubMed |
產(chǎn)品介紹 | |
產(chǎn)品圖片 |
Co-incubation of Reozalimab with PD-1-NF-AT-Jurkat and CD3L-huPD-L1-CHO-K cells and incubated for 6 hours. Bright-Lite was used to detect the fluorescent signal. As shown in fig, Reozalimab was able to block the PD-1/PD-L1 signaling pathway, and the EC50 was 0.728 nM.
Reozalimab bound to huPD-L1-CHO-K cells, and then rebounded to fluorescent secondary antibodies(Anti-human IgG, Fcγ PE) , and test by flow cytometry. As shown in fig, Reozalimab bound to huPD-L1-CHO-K cells, and the EC50 was 2.237 nM.
Reozalimab bound to huPD-1-Jurkat cells, and then rebounded to fluorescent secondary antibodies(Anti-human IgG, Fcγ PE) , and test by flow cytometry. As shown in fig, Reozalimab bound to huPD-1-Jurkat cells, and the EC50 was 0.990 nM.
Reozalimab bound to PD-L1 protein, and then rebounded to secondary antibodies(Anti-human-κ+λ-HRP) , and read OD450. As shown in fig, Reozalimab bound to huPD-L1-Fc, and the EC50 was 0.015 nM.
Reozalimab bound to PD-1 protein, and then rebounded to secondary antibodies(Anti-human-IgG-Fc-HRP) , and read OD450. As shown in fig, Reozalimab bound to huPD-1-His, and the EC50 was 0.004 nM.
Anti-PD-1 & PD-L1 Reference Antibody (Reozalimab) on SDS-PAGE under reducing (R) condition. The purity of the protein is greater than 95%.
|